Product Code: CMI6788
The uterine fibroids treatment drugs market is estimated to be valued at USD 1.87 Bn in 2024 and is expected to reach USD 3.19 Bn by 2031, growing at a compound annual growth rate (CAGR) of 7.9% from 2024 to 2031.
Report Coverage |
Report Details |
Base Year: |
2023 |
Market Size in 2024: |
US$ 1.87 Bn |
Historical Data for: |
2019 To 2023 |
Forecast Period: |
2024 To 2031 |
Forecast Period 2024 to 2031 CAGR: |
7.90% |
2031 Value Projection: |
US$ 3.19 Bn |
Figure 1.Uterine Fibroids Treatment Drugs Market Share (%), By Region, 2024
![Uterine Fibroids Treatment Drugs Market - IMG1](/sample/img/COH1477217-f1.webp)
Uterine fibroids are non-cancerous tumors that grow in or on a woman's uterus. Symptoms caused by fibroids vary in severity and include heavy or painful periods, pressure or pain in the lower abdomen, frequent urination, etc. Over-the-counter medications like ibuprofen can help relieve symptoms but do not address the underlying cause. Surgical procedures are an option but carry risks. Therefore, drug therapies that can shrink or eliminate fibroids without surgery present an attractive option for many patients. The global uterine fibroids treatment drugs market offers promising growth opportunities as researchers work to develop novel therapies.
Market Dynamics:
The growing prevalence of uterine fibroids among women coupled with the demand for non-invasive treatment options is a key factor fueling the uterine fibroids treatment drugs market growth. As per Office on Women's Health press release published in February 2021, around 20-80% women develop fibroids by the age of 50. Moreover, the limitations and risks associated with surgical procedures are further driving research into pharmaceutical therapies. However, the high costs involved in drug development pose a challenge. Additionally, lack of awareness about fibroid treatment options in developing nations also restrains market expansion. Meanwhile, emerging oral therapies in the clinical trial pipeline are expected to provide new opportunities.
Key Features of the Study:
- This report provides an in-depth analysis of the global uterine fibroids treatment drugs market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2024-2031), considering 2023 as the base year.
- It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global uterine fibroids treatment drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Myovant Sciences, Pfizer, Bayer AG, AstraZeneca, AbbVie Inc., Abbott Healthcare Pvt. Ltd., Sun Pharmaceuticals Industries Ltd., Zydus Cadila Healthcare Ltd., Gedeon Richter plc, Ipsen Pharma, Teva Pharmaceutical Industries Ltd., TerSera Therapeutics, Takeda Pharmaceutical Company Limited, Ferring Pharmaceuticals, Amring Pharmaceuticals Inc., and Biocon Biologics.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global uterine fibroids treatment drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global uterine fibroids treatment drugs market.
Market Segmentation
- Fibroid Type:
- Intramural fibroids
- Submucosal fibroids
- Subserosal fibroids
- Others
- Drug Type:
- Gonadotropin-releasing hormone (GnRH) antagonists
- Gonadotropin-releasing hormone (GnRH) agonists
- Progesterone & Contraceptives
- Hormonal Medications
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Myovant Sciences
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Fibroid Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Uterine Fibroids Treatment Drugs Market - Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 impact on the market
5. Global Uterine Fibroids Treatment Drugs Market, By Fibroid Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Intramural fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Submucosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Subserosal fibroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
6. Global Uterine Fibroids Treatment Drugs Market, By Drug Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Gonadotropin-releasing hormone (GnRH) antagonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Gonadotropin-releasing hormone (GnRH) agonists
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Progesterone & Contraceptives
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Hormonal Medications
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Uterine Fibroids Treatment Drugs Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Uterine Fibroids Treatment Drugs Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Region, 2019-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Fibroid Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer
- Bayer AG
- AstraZeneca
- AbbVie Inc.
- Abbott Healthcare Pvt. Ltd.
- Sun Pharmaceuticals Industries Ltd.
- Zydus Cadila Healthcare Ltd.
- Gedeon Richter plc
- Ipsen Pharma
- Teva Pharmaceutical Industries Ltd.
- TerSera Therapeutics
- Takeda Pharmaceutical Company Limited
- Ferring Pharmaceuticals
- Amring Pharmaceuticals Inc.
- Biocon Biologics
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact